Neurological research reveals new insights into PSP and Parkinson’s disease

Researchers have made significant findings regarding two neurodegenerative conditions. A study from Tel Aviv University suggests that the experimental drug Davunetide may be effective in treating progressive supranuclear palsy (PSP), specifically in women. While previous international clinical trials concluded the drug was not effective for the general population, a re-analysis using modern FDA-recommended methods revealed that women treated with Davunetide experienced slower disease progression, including better balance, independence in daily tasks, and preserved cognitive functions.

Separately, researchers at UT Southwestern Medical Center have identified a new sequence of abnormal brain activity associated with Parkinson’s disease. By tracking beta activity in patients undergoing deep brain stimulation surgery, the team discovered that the disease involves precisely timed events across multiple brain networks rather than being isolated to a single region. The study identified two distinct signals, low-beta and high-beta, suggesting that the coordination and direction of these signals across interconnected regions are central to understanding dopamine deficiency and its physical symptoms.